United-Guardian - UG Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.94
▲ +0.15 (2.59%)

This chart shows the closing price for UG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New United-Guardian Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UG

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for United-Guardian in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.94.

This chart shows the closing price for UG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in United-Guardian. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/25/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/19/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/13/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D)
10/30/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
(Data available from 12/5/2020 forward)

News Sentiment Rating

-0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
United-Guardian logo
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.
Read More

Today's Range

Now: $5.94
Low: $5.85
High: $5.99

50 Day Range

MA: $6.85
Low: $5.62
High: $7.87

52 Week Range

Now: $5.94
Low: $5.58
High: $11.98

Volume

12,959 shs

Average Volume

14,927 shs

Market Capitalization

$27.26 million

P/E Ratio

13.81

Dividend Yield

8.64%

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of United-Guardian?

The following Wall Street research analysts have issued research reports on United-Guardian in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for UG.

What is the current price target for United-Guardian?

0 Wall Street analysts have set twelve-month price targets for United-Guardian in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for United-Guardian in the next year.
View the latest price targets for UG.

What is the current consensus analyst rating for United-Guardian?

United-Guardian currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe UG will underperform the market and that investors should sell shares of United-Guardian.
View the latest ratings for UG.

What other companies compete with United-Guardian?

Other companies that are similar to United-Guardian include Purple Innovation, CPS Technologies, Bonk, Natuzzi and Fenbo. Learn More about companies similar to United-Guardian.

How do I contact United-Guardian's investor relations team?

United-Guardian's physical mailing address is 230 MARCUS BOULEVARD, HAUPPAUGE NY, 11788. The company's listed phone number is (631) 273-0900. The official website for United-Guardian is www.u-g.com. Learn More about contacing United-Guardian investor relations.